04 September 2010
Keywords: Cancer Research UK, Aura Biosciences, USA, KLicensing, Cancer-targeting peptides
Article | 24 December 2009
Cancer Research Technology (CRT), Cancer Research UK’s commercialization and development arm, has granted Cambridge, Massachusetts, USA-based Aura Biosciences a worldwide licence to use its cancer-targeting peptides in delivering cancer treatments directly to the tumour.
These peptides bind to a protein on the surface of the cell called integrin alpha v beta 6, a protein complex that is found at high levels on many tumor cells but is absent in most normal tissues. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.